Literature DB >> 24073305

Lack of Association between COX-2 Staining Level and Biochemical Recurrence Following Salvage Radiation Therapy for Recurrent Prostate Cancer.

Michael G Heckman1, Katherine S Tzou, Alexander S Parker, Thomas M Pisansky, Steven E Schild, Tracy W Hilton, Vivek N Patel, Liset Pelaez, Li Yan Khor, Jennifer L Peterson, Larry C Daugherty, Laura A Vallow, Alan Pollack, Steven J Buskirk.   

Abstract

OBJECTIVE: The ability to predict which men will experience biochemical recurrence (BCR) after salvage radiation therapy (SRT) for recurrent prostate cancer following radical prostatectomy has potential for improvement. Cyclooxygenase-2 (COX-2) overexpression has previously correlated with poor clinical outcomes following primary treatment for prostate cancer, however its predictive ability in the specific setting of SRT has not been examined to date. This study evaluated the association between COX-2 staining intensity and BCR following SRT for recurrent prostate cancer.
METHODS: We utilized a cohort of 151 patients who underwent SRT between July 1987 and July 2003. COX-2 staining intensity in primary tumor samples was detected using monoclonal antibodies and quantified using a computer-assisted method. The association between COX-2 staining intensity and BCR was evaluated using multivariable Cox regression models.
RESULTS: When examining COX-2 staining level as three-level categorical variable (low, moderate, high) based on approximate sample tertiles, there was no evidence of an association with BCR (P=0.18). More specifically, in comparison to patients with low staining intensity, there was no significant difference in risk of BCR for moderate (Relative risk [RR]: 1.17, P=0.56) or high (RR: 0.72, P=0.22) COX-2 staining intensity patients. This lack of association was also observed when considering COX-2 staining intensity as a continuous variable (RR: 0.83, P=0.15).
CONCLUSION: Our results indicate that COX-2 staining intensity is likely of little use in discriminating prognosis of SRT. It appears that the search for prognostic factors associated with BCR should continue elsewhere in order to further enhance patient selection for SRT.

Entities:  

Keywords:  biochemical recurrence; prostate cancer; salvage radiation therapy; tumor biomarker

Year:  2013        PMID: 24073305      PMCID: PMC3780452          DOI: 10.1007/s13566-013-0099-2

Source DB:  PubMed          Journal:  J Radiat Oncol        ISSN: 1948-7908


  17 in total

1.  Evaluation of B7-H3 expression as a biomarker of biochemical recurrence after salvage radiation therapy for recurrent prostate cancer.

Authors:  Alexander S Parker; Michael G Heckman; Yuri Sheinin; Kevin J Wu; Tracy W Hilton; Nancy N Diehl; Thomas M Pisansky; Steven E Schild; Eugene D Kwon; Steven J Buskirk
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-07-02       Impact factor: 7.038

2.  Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.

Authors:  Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario Eisenberger; Frederick J Dorey; Patrick C Walsh; Alan W Partin
Journal:  JAMA       Date:  2005-07-27       Impact factor: 56.272

3.  Immunohistochemical expression of Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens.

Authors:  J Rubio; D Ramos; J A López-Guerrero; I Iborra; A Collado; E Solsona; S Almenar; A Llombart-Bosch
Journal:  Eur Urol       Date:  2005-07-11       Impact factor: 20.096

4.  Natural history of progression after PSA elevation following radical prostatectomy.

Authors:  C R Pound; A W Partin; M A Eisenberger; D W Chan; J D Pearson; P C Walsh
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

Review 5.  Cyclooxygenase-2 and prostate carcinogenesis.

Authors:  Tajamul Hussain; Sanjay Gupta; Hasan Mukhtar
Journal:  Cancer Lett       Date:  2003-03-10       Impact factor: 8.679

6.  Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy.

Authors:  Bruce J Trock; Misop Han; Stephen J Freedland; Elizabeth B Humphreys; Theodore L DeWeese; Alan W Partin; Patrick C Walsh
Journal:  JAMA       Date:  2008-06-18       Impact factor: 56.272

7.  Cyclooxygenase-2 expression is associated with vascular endothelial growth factor-C and lymph node metastases in human prostate cancer.

Authors:  Jin-Ming Di; Jing Zhou; Xu-Long Zhou; Xin Gao; Chun-Qui Shao; Jun Pang; Qi-Peng Sun; Yan Zhang; Xing-Xing Ruan
Journal:  Arch Med Res       Date:  2009-06-04       Impact factor: 2.235

8.  Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.

Authors:  Andrew J Stephenson; Peter T Scardino; Michael W Kattan; Thomas M Pisansky; Kevin M Slawin; Eric A Klein; Mitchell S Anscher; Jeff M Michalski; Howard M Sandler; Daniel W Lin; Jeffrey D Forman; Michael J Zelefsky; Larry L Kestin; Claus G Roehrborn; Charles N Catton; Theodore L DeWeese; Stanley L Liauw; Richard K Valicenti; Deborah A Kuban; Alan Pollack
Journal:  J Clin Oncol       Date:  2007-05-20       Impact factor: 44.544

9.  Cyclooxygenase-2 (COX-2) expression is an independent predictor of prostate cancer recurrence.

Authors:  Brian L Cohen; Pablo Gomez; Yohei Omori; Robert C Duncan; Francisco Civantos; Mark S Soloway; Vinata B Lokeshwar; Bal L Lokeshwar
Journal:  Int J Cancer       Date:  2006-09-01       Impact factor: 7.396

10.  Evaluation of ki-67 staining levels as an independent biomarker of biochemical recurrence after salvage radiation therapy for prostate cancer.

Authors:  Alexander S Parker; Michael G Heckman; Kevin J Wu; Julia E Crook; Tracy W Hilton; Thomas M Pisansky; Johnny R Bernard; Steven E Schild; Li Yan Khor; Elizabeth H Hammond; Alan Pollack; Steven J Buskirk
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-05-21       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.